PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:09 AM ET

Sponsor Check › Person

KL
No photo found yet (own website and image search run after this page is viewed)

Kevin Li

Named as an officer, director or promoter on SEC Form D filings · CA · Jul 16, 2015 → Jul 7, 2021

5deals (issuers)
$183.8Mreported sold
83investors
15Form D filings
2015–2021years on file

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:34 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Kevin Li is listed as a director on 15 SEC Form D filings by 5 issuers between Jul 2015 and Jul 2021: Neurelis, Inc. (San Diego, CA — biotechnology — 2015–2021; $114.8M reported sold to 26 investors), Qpex Biopharma, Inc. (San Diego, CA — biotechnology — 2018–2019; $27.4M reported sold to 11 investors), JumpCode Genomics, Inc. (San Diego, CA — biotechnology — 2020; $21M reported sold to 8 investors), Multiverse, Inc. (San Francisco, CA — other technology — 2021; $17.7M reported sold to 21 investors) and iGenomX International Genomics Corp (Carlsbad, CA — industry reported as "Other" — 2019; $3.02M reported sold to 17 investors).

What this means A repeat sponsor — 5 separate companies raised money with this person listed as director, over about 6 years. Across those companies the filings report $183.8M sold in total.

Listed alongside Craig C. Chambliss (8 shared filings), David F. Hale (8 shared filings), Priyanka Belawat (7 shared filings), George Stuart (6 shared filings), Cam L. Garner (4 shared filings) and 20 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Kevin. Each name links to their own page.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 15 public filings for Kevin Li and found 8 differences, 2 worth asking the sponsor about: Form D filed 175 days after the first sale; Form D filed 109 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Kevin Li has not run yet — it is joining a line of 8,220 names; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:34 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Kevin Li..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

Kevin Li closed
United States Bankruptcy Court, N.D. California · No. 95-51157 · Filed Feb 24, 1995 · Closed Oct 9, 1996
Role of Kevin Li: Debtor · Outcome: Case closed 1996-10-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (rare in federal dockets); 2 people with this name in Form D filings; court in the person's filing state (CA)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:34 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

8 differences found between the filings for Kevin Li — 2 worth asking about (compared 15 filings on Oct 24, 2026)

Worth asking · Jan 13, 2021 – Jul 7, 2021

Form D filed 175 days after the first sale — Multiverse, Inc.

The filing says the first sale was Jan 13, 2021. The Form D was filed Jul 7, 2021 — 175 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 160 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Worth asking · Oct 17, 2019 – Feb 3, 2020

Form D filed 109 days after the first sale — Neurelis, Inc.

The filing says the first sale was Oct 17, 2019. The Form D was filed Feb 3, 2020 — 109 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 94 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Note · Aug 7, 2018 – Aug 24, 2018

Form D filed 17 days after the first sale — Neurelis, Inc.

The filing says the first sale was Aug 7, 2018. The Form D was filed Aug 24, 2018 — 17 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 2 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Note · Feb 3, 2020 – Oct 16, 2020

Offering amount changed between filings — Neurelis, Inc.

The Feb 3, 2020 filing says $15,348,001 offered; the Oct 16, 2020 Form D/A says $42,098,007.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Sources
Note · Oct 16, 2018 – Aug 1, 2019

Offering amount changed between filings — Qpex Biopharma, Inc.

The Oct 16, 2018 filing says $33,075,000 offered; the Aug 1, 2019 Form D/A says $41,075,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Sources
Note · Jul 2, 2015 – Mar 8, 2021

6 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Neurelis, Inc. (latest filing Mar 8, 2021) · No amendment in the last 12 months on an offering that may still be open — Qpex Biopharma, Inc. (latest filing Aug 1, 2019) · No amendment in the last 12 months on an offering that may still be open — iGenomX International Genomics Corp (latest filing Apr 23, 2019) · No amendment in the last 12 months on an offering that may still be open — Neurelis, Inc. (latest filing Aug 24, 2018) · No amendment in the last 12 months on an offering that may still be open — Neurelis, Inc. (latest filing Dec 7, 2017) · and 1 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Sources
Note · Jul 23, 2021 – Jul 23, 2026

Same name, different state: "Kevin Li" (MO) is a separate record

This page covers filings where the address state is CA. A separate record, "Kevin Li" with address state MO, is listed on 4 filings — most recently by Allotera Therapeutics, Inc. (Jul 23, 2026). The two records do not overlap in time: this page runs Jul 16, 2015 to Jul 7, 2021; the other runs Jul 23, 2021 to Jul 23, 2026.

What this means Could be the same person who moved, or two people with the same name. We keep them apart until a filing ties them together. Check both pages before you decide.

Sources
Note · Jul 16, 2015 – Jan 6, 2017

Address moved from Encinitas, CA to San Diego, CA — Neurelis, Inc.

The people listed on the Jul 16, 2015 filing give Encinitas, CA; on the Jan 6, 2017 filing they give San Diego, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

1 of 12 offerings reports sales commissions totalling $2,400,000; 0 report finder's fees; 0 report proceeds to related persons.

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jul 7, 2021 D
Multiverse, Inc.
File 021-405410
$0$0$0None listed on this filingEDGAR ↗
Mar 8, 2021 D
Neurelis, Inc.
File 021-391462
$2,400,000$0$0Aquilo Partners, L.P. BrokerCheck CRD 114909 ↗EDGAR ↗
Dec 26, 2020 D
JumpCode Genomics, Inc.
File 021-384310
$0$0$0None listed on this filingEDGAR ↗
Oct 16, 2020 D/A
Neurelis, Inc.
File 021-359627
$0$0$0None listed on this filingEDGAR ↗
Feb 11, 2020 D
JumpCode Genomics, Inc.
File 021-360303
$0$0$0None listed on this filingEDGAR ↗
Aug 1, 2019 D/A
Qpex Biopharma, Inc.
File 021-323670
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2019 D
iGenomX International Genomics Corp
File 021-337936
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2019 D
iGenomX International Genomics Corp
File 021-337943
$0$0$0None listed on this filingEDGAR ↗
Nov 20, 2018 D
Neurelis, Inc.
File 021-326282
$0$0$0None listed on this filingEDGAR ↗
Aug 24, 2018 D
Neurelis, Inc.
File 021-320006
$0$0$0None listed on this filingEDGAR ↗
Dec 7, 2017 D/A
Neurelis, Inc.
File 021-277803
$0$0$0None listed on this filingEDGAR ↗
Jul 16, 2015 D
Neurelis, Inc.
File 021-243911
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 5

Every issuer that named Kevin Li on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Other Technology

Multiverse, Inc.

San Francisco, CA · Jul 7, 2021
  • Jul 7, 2021 · D · $17,669,936 sold of $17,669,936 · 21 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $17.7M from 21 investors (100% of the $17.7M target) as of the latest filing. Kevin is listed as director.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Neurelis, Inc.

San Diego, CA · Jul 16, 2015 → Mar 8, 2021 · 8 filings
  • Mar 8, 2021 · D · $114,759,923 sold of $120,021,902 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 16, 2020 · D/A · $42,098,007 sold of $42,098,007 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 3, 2020 · D · $15,348,001 sold of $15,348,001 · 25 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 20, 2018 · D · $40,500,000 sold of $40,500,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 24, 2018 · D · $5,200,000 sold of $15,000,000 · 11 investors · min. $50,000 · role: Director EDGAR ↗
  • Dec 7, 2017 · D/A · $15,000,000 sold of $20,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 6, 2017 · D · $10,000,000 sold of $20,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 16, 2015 · D · $1,500,000 sold of $10,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $114.8M from 26 investors (96% of the $120M target) as of the latest filing. Kevin is listed as director on 8 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

JumpCode Genomics, Inc.

San Diego, CA · Feb 11, 2020 → Dec 26, 2020 · 2 filings
  • Dec 26, 2020 · D · $21,012,997 sold of $21,012,997 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 11, 2020 · D · $1,500,000 sold of $1,500,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $21M from 8 investors (100% of the $21M target) as of the latest filing. Kevin is listed as director on 2 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Qpex Biopharma, Inc.

San Diego, CA · Oct 16, 2018 → Aug 1, 2019 · 2 filings
  • Aug 1, 2019 · D/A · $27,383,333 sold of $41,075,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 16, 2018 · D · $22,050,000 sold of $33,075,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $27.4M from 11 investors (67% of the $41.1M target) as of the latest filing. Kevin is listed as director on 2 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other

iGenomX International Genomics Corp

Carlsbad, CA · Apr 23, 2019 → Apr 23, 2019 · 2 filings
  • Apr 23, 2019 · D · $1,501,072 sold of $1,526,356 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 23, 2019 · D · $606,778 sold of $606,778 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.02M from 17 investors (100% of the $1.53M target) as of the latest filing. Kevin is listed as director on 2 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Kevin Li — MO, 1 issuer, Jul 23, 2021 → Jul 23, 2026 · no shared issuer

People around Kevin 25

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

David F. Hale

Director · 8 shared filings (1 issuer) · also on 18 other issuers

David F. Hale is on 19 issuers in total — a repeat sponsor. Their page lists every one.

CC
No photo found yet (own website and image search run after this page is viewed)
Person

Craig C. Chambliss

Executive Officer, Director · 8 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Priyanka Belawat

Director · 7 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

GS
No photo found yet (own website and image search run after this page is viewed)
Person

George Stuart

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Cam L. Garner

Director · 4 shared filings (1 issuer) · also on 11 other issuers

Cam L. Garner is on 12 issuers in total — a repeat sponsor. Their page lists every one.

YZ
No photo found yet (own website and image search run after this page is viewed)
Person

Yong Zhang

Director · 4 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Keith Brown

Executive Officer, Director · 4 shared filings (2 issuers)

Listed on the same filings as Kevin Li. Their page shows their other deals.

HP
No photo found yet (own website and image search run after this page is viewed)
Person

Huaizheng Peng

Director · 4 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

EC
No photo found yet (own website and image search run after this page is viewed)
Person

Eugene Chen

Director · 3 shared filings (2 issuers) · also on 5 other issuers

Eugene Chen is on 7 issuers in total — a repeat sponsor. Their page lists every one.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

Joel Rotroff

Director · 3 shared filings (2 issuers)

Listed on the same filings as Kevin Li. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carol Gallagher

Director · 2 shared filings (1 issuer) · also on 14 other issuers

Carol Gallagher is on 15 issuers in total — a repeat sponsor. Their page lists every one.

DB
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel D Burgess

Director · 2 shared filings (1 issuer) · also on 7 other issuers

Daniel D Burgess is on 8 issuers in total — a repeat sponsor. Their page lists every one.

KM
No photo found yet (own website and image search run after this page is viewed)
Person

Kirk Malloy

Director · 2 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

DR
No photo found yet (own website and image search run after this page is viewed)
Person

Douglas Reed

Director · 2 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

MD
No photo found yet (own website and image search run after this page is viewed)
Person

Michael N. Dudley

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

SC
No photo found yet (own website and image search run after this page is viewed)
Person

Stephen Cartt

Director · 2 shared filings (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

TG
No photo found yet (own website and image search run after this page is viewed)
Person

Terry Gould

Director · 2 shared filings (1 issuer) · also on 10 other issuers

Terry Gould is on 11 issuers in total — a repeat sponsor. Their page lists every one.

ML
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Liang

Director · 1 shared filing (1 issuer) · also on 12 other issuers

Michael Liang is on 13 issuers in total — a repeat sponsor. Their page lists every one.

FW
No photo found yet (own website and image search run after this page is viewed)
Person

Frank Witney

Director · 1 shared filing (1 issuer) · also on 2 other issuers

Listed on the same filings as Kevin Li. Their page shows their other deals.

YH
No photo found yet (own website and image search run after this page is viewed)
Person

Yaron Hakak

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

DK
No photo found yet (own website and image search run after this page is viewed)
Person

Dan Kidle

Director · 1 shared filing (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

HB
No photo found yet (own website and image search run after this page is viewed)
Person

Hisham Bedri

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

TL
No photo found yet (own website and image search run after this page is viewed)
Person

Tiffany Li

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

SA
No photo found yet (own website and image search run after this page is viewed)
Person

Sara Alfageeh

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Thariq Shihipar

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Kevin Li. Their page shows their other deals.

Registrations and other filings

Adviser registration (Form ADV)

None of the 5 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Kevin Li by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 5 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Kevin Li is listed on: none on file. No website or social profile named in Qpex Biopharma, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #231,672 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (San Diego, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Kevin Li appears on a new Form D, or when a court case or SEC action is matched to them. See plans →